Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial
William H. Marks(Bellevue College), Denis Glotz(Metabolism and Renal Physiology), Nizam Mamode(Guy's Hospital), Lloyd E. Ratner(Columbia University Irving Medical Center), Judith A. Boice(Alexion Pharmaceuticals (United States)), Mark D. Stegall(Mayo Clinic in Arizona), Lynn D. Cornell(University of Calgary), Ajda T. Rowshani(Erasmus MC), Robert B. Colvin(Harvard University), Bradley Dain(Alexion Pharmaceuticals (United States)), Robert A. Montgomery(New York University)
Cited by 146
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
|Kidney International|1993|1.5k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k